Ongoing Clinical Trials for Vestibular Disorder
There is currently 1 ongoing clinical trial for vestibular disorder, specifically focused on Menière’s disease, a condition affecting the inner ear that causes episodes of vertigo, hearing loss, and tinnitus. This trial is investigating whether injections of methylprednisolone directly into the ear can help reduce the frequency of vertigo attacks compared to placebo treatment.
Clinical trial locations
Study on Meniere’s Disease: Comparing Methylprednisolone and Placebo for Patients with Unilateral Meniere’s Disease
This clinical trial is examining whether methylprednisolone, a corticosteroid medication, can effectively reduce vertigo attacks in patients with Menière’s disease. Menière’s disease is a disorder of the inner ear that causes episodes of spinning sensations (vertigo), hearing loss, ringing in the ears (tinnitus), and a feeling of fullness or pressure in the ear. The condition typically affects only one ear and can significantly impact daily life due to the unpredictability of vertigo episodes.
Main inclusion criteria: To participate in this trial, you must have been diagnosed with unilateral Menière’s disease, meaning the condition affects only one ear. You must be over 18 years old and have experienced at least 4 vertigo attacks in the past 6 months. The trial is open to both males and females.
Main exclusion criteria: You cannot participate if you do not have unilateral Menière’s disease or if you belong to a vulnerable population (such as pregnant women or those unable to give consent). Other reasons for exclusion include currently participating in another clinical trial, having allergies to the study medication, having other medical conditions that might interfere with the study, having had recent surgery that could affect the results, or being unable to follow study procedures or attend follow-up visits.
Focus and goal: The primary goal of this trial is to determine whether intratympanic injections of methylprednisolone (injected directly into the ear) are more effective than placebo in reducing the frequency of vertigo attacks over a one-year period. The study will also monitor participants’ quality of life, including aspects related to dizziness and tinnitus. Participants will undergo regular assessments and follow-up visits to track their response to treatment.
Investigational drug: The trial uses methylprednisolone, a corticosteroid medication administered at a dosage of 62.5 mg/ml. This medication works by reducing inflammation and suppressing the immune response in the inner ear. By delivering the medication directly into the ear through intratympanic injection, it can target the affected area more effectively. The anti-inflammatory properties of methylprednisolone are intended to decrease the inflammation that contributes to vertigo episodes in Menière’s disease.
Summary
Currently, there is one active clinical trial addressing vestibular disorder, specifically targeting Menière’s disease. This trial is being conducted in the Netherlands and focuses on evaluating the effectiveness of methylprednisolone injections compared to placebo in managing vertigo attacks. The study represents an important effort to find better treatment options for patients experiencing the debilitating symptoms of Menière’s disease, particularly the unpredictable episodes of vertigo that can significantly affect quality of life. The use of intratympanic injections allows for targeted delivery of the corticosteroid medication directly to the affected ear, potentially offering more effective symptom control with fewer systemic side effects.
